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Abstract 
BACKGROUND: Kaposi’s sarcoma was first described in 1872 by Moritz Kaposi. To date, it is considered a 
malignant disease is originating from the endothelial cells of the lymphatic vessels believed to be infected with 
HHV-8. The current classification defines four major epidemiological forms of Kaposi’s sarcoma: classical, 
endemic, AIDS-associated, and iatrogenic. 
CASE REPORT: A 90-year-old male is presented with multiple plaques- and tumour-shaped brown-violet 
formations located on an erythematous-livid base in the area of both feet and both shanks. Two samples were 
taken from the lesions on the skin of the shanks, with histopathological examination and the subsequent 
immunohistochemistry showing Kaposi’s sarcoma. 
CONCLUSIONS: Kaposi sarcoma is a disease that causes difficulties both in diagnostic and therapeutic respect. 
The only sure way to determine the correct diagnosis is immunohistochemical staining with the anti-HHV8 
antibody. Despite the wide range of systematic and local treatment options, there is still no unified algorithm and a 
unified strategy for the treatment of Kaposi’s sarcoma. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Kaposi’s sarcoma is a tumour originating from 
endothelial cells where there is a suspected infection 
with human herpesvirus-8 (HHV-8) [1]. It is the most 
common malignancy among the AIDS patients [2]. 
The clinical picture and the standard histology are not 
always sufficient for Kaposi’s sarcoma to be as 
precise as possible distinguished from some other 
diseases [3]. In these cases, the conduct of an 
immunohistochemical study to determine the correct 
diagnosis is of paramount importance [4].  
Five major subtypes of Kaposi’s sarcoma can 
be differentiated: (1) classical type of predominantly 
older Caucasian males; (2) endemic Kaposi’s 
sarcoma of the Sub-Sahara region, which is not HIV-
associated; (3) transplantation- and 
immunosuppression-associated type; (4) AIDS-related 
type; (5) classical type in HIV-positive patients. 
There is still no established golden standard 
in the treatment of Kaposi’s sarcoma, but there are 
some therapeutic options that show complete or 
partial remissions [5].  
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Case Report 1 
 
A 90-year-old man is presented at the 
Department of Dermatology and Dermatologic 
Surgery at the Medical Institute of Ministry of Interior, 
(MVR-Sofia), Bulgaria, who suffers from chronic 
venous insufficiency and benign prostatic hyperplasia. 
The patient was hospitalised due to the presence of 
multiple plaque-shaped to tumour-shaped formations 
in the area of the left leg. The lesions date back to 
approx. 2 years, due to which lesions the patient had 
two previous hospitalisations in other health 
institutions and conducted antibiotic and corticosteroid 
therapy without success. During the dermatological 
examination, in the area of both feet and the two 
shanks, the presence of brown-violet tumor-shaped 
formations was found with a diameter of 0.5 to 2.0 cm, 
located on an erythematous-livid base (Figure 1a, 1b 
and 1c).  
 
Figure 1: a), b) and c) - Kaposi sarcoma lesions on the left and right 
lower extremities-presence of nodules, blisters and 
hyperpigmentation 
 
The left-sided pathological changes were 
clinically more pronounced (Figure 1a). The available 
clinical picture was suspected for Kaposi’s sarcoma. 
Samples were taken of the tumour-shaped formations, 
on the skin of both shanks for histological verification 
of the diagnosis determined.  
 
Figure 2: Kaposi sarcoma. Histopathology (H&E); a) Under a slight 
acanthotic epidermis vascular tumour with partially high cellularity 
(x40); b) Atypical spindle cells with small slit-like vascular spaces. 
Preexisting vessels are in part surrounding by spindle cells, this 
way appearing freely floating, so-called promontory sign (x100); c) 
Vascular lining by atypical, in part hyperchromatic spindle cells. 
Extravasated red blood cells (x400); d) In part additional plasma 
cells in the infiltrate (x400) 
The histopathological examination and 
subsequent immunohistochemistry showed definite 
evidence of Kaposi’s sarcoma (Figures 2a, 2b, 2c, 2d, 
3a, 3b, 4a, 4b and 4c). 
 
Figure 3: Kaposi sarcoma histopathology - a) among tumour cells 
hemosiderin deposits; b) many extravasated red blood cells 
 
The ultrasound examination performed on the 
lower extremities revealed the presence of enlarged 
and pathologically changed lymph nodes in the left 
femoral triangle. 
 
Figure 4: Kaposi sarcoma-immunohistochemistry - a), b) and c) 
Tumor cells are labelled with antibodies against CD31, podoplanin, 
and HHV8 
 
Systemic therapy with Ceftriaxone was 
performed 2 g x 1/day IV for 7 days, and the local 
therapy included daily iodasept ointment dressings for 
7 days. Nadroparin calcium was prophylactically 
applied 0.4 x 1/day SC for 7 days. As a result of the 
conducted treatment, lymph node subsiding was 
observed, and the patient was redirected to perform 
radiation therapy at a specialised oncology centre.  
 
 
Case Report 2 
 
A 76-year-old male patient presented with 
several nodules on his left forefoot and lower leg 
which developed during the last 6 months. He 
reported burning and pain sensations on the ulcerated 
lesions located on the 2nd and 3rd left toe. His 
medical history was remarkable for prostate cancer, 
nephrectomy because of a cirrhotic kidney and a first-
grade atrioventricular block. On examination, we 
observed multiple livid or soft brownish nodules on the 
left lower leg and forefoot with ulcerations on the toes. 
Enlarged lymph nodes were palpable in both groins. 
A skin biopsy was taken for histopathology. 
Within the dermis, bizarre formed; partly ectatic blood 
vessels with prominent endothelial and positive 
promontories sign, extravasation of red blood cells 
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and siderophages were noted. The vascular parts 
within papillary bodies showed a spindle cell type. 
Endothelial were positive for CD31, podoplanin, and 
HHV-8 and partially for CMYK by 
immunohistochemistry. The mitotic rate was about 10 
to 20% with Ki67-staining. Diagnosis: Classical KS is 
shifting from patch to plaque stage.Laboratory 
findings: Lymphopenia of 12% (normal range: 25-
45%), erythrocytes 4.29 (4.6-6.2Tpt/l), Hb 7.9 (8.6-
12.1mmol/l), ß-2-microglobulin 2.6 (0.8-2.2mg/l), 
CD3+/CD4+-T-helper cells 79.8 (35-66%), 
CD3+/CD8+-T-suppressor cells 11.1 (17-46%), ratio 
helper/ suppressor cells 7.19 (1.0-2.3), HIV test 
negative. Imaging: Computerized tomography 
demonstrated a pulmonary nodule of 0.5cm in 
diameter dorsobasilar on his right side. Several Hilary 
and pulmonary lymph nodes with a diameter < 1 cm. 
Ultrasound abdomen/ groins: Tumor-like growth in the 
left groin and an atypical lymph node (19 mm). MRI of 
the head excluded any tumour spread. The patient 
was referred to the Department of Radiology for 
radiotherapy. 
 
Figure 5: Case #2: a) Nodules on the lower left leg and foot. Left 
Lower leg with patches and plaques of classical KS; b) 
Immunostaining for CD31; c) Immunostaining for CD34; d) 
Immunostaining for HHV-8 
 
 
Discussion 
 
Kaposi’s sarcoma (KS) was first described in 
1872 in an article titled “Idiopathic multiple pigmented 
sarcoma of the skin” by Moritz Kaposi and to this day 
is named after him [6]. Tommaso de Amicis-an Italian 
dermatologist, confirmed his findings, albeit ten years 
later [7]. In 1981, Alvin Friedman-Kein changed the 
perceptions that KS is a rare disease affecting 
predominantly senior men and gives a whole new 
perspective by concluding that Kaposi’s sarcoma can 
be HIV-associated [8]. The subsequent 
epidemiological studies in people with AIDS revealed 
two important features of this disease, namely that it is 
possible to be sexually transmitted as is HIV, on the 
one hand, and on the other, immunosuppression 
promotes the development of Kaposi’s sarcoma [2]. 
Still, the genesis of this type of sarcoma is not 
fully elucidated [9]. Currently, the leading theory is that 
Kaposi’s sarcoma is a tumour originating from the 
endothelium of the blood vessels that are most 
commonly associated with Kaposi’s sarcoma 
herpesvirus/human herpesvirus 8 (KSHV/HHV8) 
infection [1] [10] [11]. It is believed that it is this virus 
that is the cause of a change in the differentiation and 
the function of the endothelial cells, resulting in the 
appearance of altered vascular structures to a 
lymphatic phenotype and determining the 
angioproliferative character of KS [1] [12]. A possible 
explanation for this mechanism is that this occurs with 
the involvement of VEGFR3-lymphatic endothelial-
cell-specific receptor important for lymphangiogenesis 
[12]. It is considered that the transcription factor Its-1 
activates the promoter of VEGFR3 and thus he plays 
a role in KSHV activation of endothelial cells during 
latent KSHV infection [12]. It is Its-1 that is considered 
to be the regulator involved in the induction of 
angiogenic phenotypes by KSHV [12]. As a rule, this 
type of sarcoma includes four types of forms: 
classical, African (endemic), AIDS-associated 
(epidemic) and iatrogenic (organ transplant-related) 
form [10] (Table 1). There is also another form of 
Kaposi-the so-called lymphadenopathic Kaposi’s 
sarcoma, which can occur in people with AIDS but 
also in immunocompetent children or adults [13] [14] 
[15]. It affects the lymph nodes, the internal organs, 
the gastrointestinal tract and it can pass into a 
disseminated form with an aggressive course of 
progression [15]. 
Table 1: Variants of Kaposi’s sarcoma 
Variant Risk Group Median survival 
Classic Senior men of Eastern 
European or Mediterranean 
origin 
Years or decades 
Endemic African children and adults Months or years 
Immunosuppression- 
associated, or transplantation- 
associated 
Organ transplant recipients Months or years 
AIDS-associated Persons infected with human 
immunodeficiency virus, 
especially homosexual or 
bisexual men 
Weeks or months 
Classical KS in HIV-positive 
patients 
HIV-positive younger patients Months or years 
 
Usually, the lesions of Kaposi’s sarcoma go 
through three stages: 1) early with the appearance of 
macules (patch stage), 2) followed by the appearance 
of plaques (plaque stage), and finally, 3) nodules 
(tumour stage) [10] [11] [16]. At the same time, there 
is also data in the literature for more specific 
histological variants that include anaplastic, 
hyperkeratotic, lymphangioma-like, bullous, 
telangiectatic, ecchymotic, keloidal, pyogenic 
granuloma-like, micronodular, intravascular, 
glomeruloid and pigmented KS, KS with sarcoid-like 
granulomas and KS with myoid nodules [10] [11]. 
In a historical aspect, Kaposi’s sarcoma is 
described as a disease primarily affecting men of 
Mediterranean origin, as our patient, with a pre-target 
location, the lower limbs and slow progression [17]. 
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Risk factors associated with KS include male gender, 
HLA-DR5 genetic marker, homosexuality, 
immunosuppression and viral agents such as 
Cytomegalovirus [17]. It is believed that in patients 
with HIV infection, KS may occur at any time, most 
commonly when CD4 count < 200 cells/mm
3
 [14]. For 
this reason, their number is used as a prognostic 
factor for the evolution of Kaposi’s sarcoma, and CD4 
count > 200/mm
3
 and only cutaneous involvement [18] 
is considered to be a good prognosis. Thus, the 
immunosuppression after organ transplantation or in 
AIDS can form the two groups of patients at highest 
risk and incidence of Kaposi’s sarcoma [2] [19]. 
Histopathological, the Kaposi’s sarcoma is 
characterised by the presence of hyaline bodies, 
deposits of hemosiderin, spindle cell and the 
formation of vascular channels between spindle cells 
[3] [16]. It is these features that determine the range of 
diseases that should be considered in a differential 
diagnosis-granuloma pyogenicum, leiomyoma, 
leiomyosarcoma or fibrosarcoma [3]. Besides these, a 
diagnostic error can also occur with dermatofibroma, 
hemangioma or scar [20]. Difficulties may also result 
from the localization of KS [21]. Although it is typical 
that the lymph nodes and the visceral organs are 
affected, an atypical clinical manifestation is also 
possible, covering other anatomical areas such as the 
musculoskeletal system, central and peripheral 
nervous system, larynx, eye, major salivary glands, 
endocrine organs, heart, thoracic duct, urinary 
system, breast, sites of previous iatrogenic trauma 
(wounds) and blood clots is also presented [21].  
The performance of immunohistochemistry 
and immunohistochemical reactivity for CD31, CD34, 
D2-40 and FLI1 [4] [22], is of crucial importance for 
determining the diagnosis. The results of the 
immunohistochemistry and the sensitivity for these 
markers were found to be the same in AIDS-related 
and non-AIDS-related KS, as well as between the 
nodular-and patch/plaque-stage KS [22]. Furthermore, 
due to the possibility of a lymphangioma-like Kaposi’s 
sarcoma and the existing risk of an incorrect diagnosis 
of lymphangioendothelioma, it is important to perform 
immunohistochemical staining with anti-HHV8 
antibody [23]. The same also applies to conditions 
with chronic lymphoedema when KS can be mistaken 
with the Stewart-Treves Syndrome (STS) [24]. The 
difference between them is that KS does not 
necessarily require the presence of lymphedema for 
its development and is etiologically associated with a 
viral infection that is lacking in STS [25].  
Difficulties in the clinical diagnosis are often 
also created in the cases of pseudo-Kaposi's 
sarcoma-acroangiodermatitis, and again only the 
HHV-8 study can distinguish it from KS [26]. 
Cutaneous angiosarcoma (CAS) is another 
interesting tumour that also has a vascular origin and 
should be distinguished from Kaposi sarcoma [27]. It 
is believed that programmed death-1 (PD-1) and 
programmed death ligand-1 (PD-L1) expression by 
tumour cells play a key role in the angiosarcoma 
pathogenesis [27]. However, there are cases in which 
1) angiosarcoma can detect PD-L1 negativity in 
immunohistochemistry, 2) even more interesting- to 
be affected by PD-1 inhibitor therapy with 
pembrolizumab despite this negativity and 3) when it 
comes to lesions of vascular origin a guarantee for 
confirmation or exclusion of Kaposi's sarcoma 
diagnosis is only HHV- 8 positivity [23] [27]. 
Currently, a wide range of options is used for 
treatment of Kaposi’s sarcoma that include 
chemotherapy, radiotherapy, immunotherapy, 
cytotoxic agents, liposomal anthracyclines, paclitaxel, 
retinoic acids, pazopanib as well as some 
antiangiogenic agents such as AGM 1470 (TNP 470), 
thalidomide and glutamine disodium (IM 862), that 
show promising results [5] [28]. Self-administered or in 
combination, the chemotherapeutic agents provide 
acceptable results, but recurrences of KS occur 
frequently, and the progression-free periods are often 
short [29].  
For classical KS, which is radiosensitive, the 
radiotherapy is of key importance in the therapy of all 
forms. It has the greatest effect in the early stages of 
the disease [30] [31]. However, as it reduces the pain, 
oedema and ensures control of the bleeding, 
radiotherapy can also be used as a palliative 
treatment in advanced cases of KS [31] [32]. In this 
regard, doses of 15.2 Gy for oral lesions and 20 Gy 
for lesions involving conjunctiva, eyelids, lips, hands, 
feet, penis, and anal region provide good control of 
the symptoms [33]. For the other parts of the body, a 
dose of 30 Gy may be used, with the hypofractioning 
showing the best outcome regarding recurrence-free 
survival, the toxicity and the local control [34]. In non-
AIDS associated KS (NAKS), radiotherapy provides a 
very good therapeutic control [34].  
For patients with AIDS-related Kaposi’s 
sarcoma, however, the first line of treatment is the 
high-activity antiretroviral therapy (HAART) [5]. There 
is evidence that even a self-administered HAART 
therapy may lead to spontaneous regression of KS in 
AIDS patients [35]. The spontaneous regression is 
described in the literature and discontinuation of 
immunosuppressive treatment in the iatrogenic form 
of KS after transplantation [36]. More surprising in this 
respect is the data from a documented partial 
regression in cases of non-HIV, non-iatrogenic Kaposi 
sarcoma [37]. The precise mechanisms under which 
this is done are still within the hypothetical sphere 
[37].  
The WHO has developed international 
guidelines for HIV-associated KS, but there is still no 
standardised approach to the treatment of other types 
of Kaposi’s sarcoma [5] [38].  
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